DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yamazaki, M.
Right arrow Articles by Sugiyama, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamazaki, M.
Right arrow Articles by Sugiyama, Y.

0090-9556/97/2510-1123-1129$02.00/0
DRUG METABOLISM AND DISPOSITION
Copyright © 1997 by The American Society for Pharmacology and Experimental Therapeutics
Vol. 25, No. 10


ARTICLE
Biliary Excretion of Pravastatin in Rats: Contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter (CMOAT)

Masayo Yamazaki, Sayoko Akiyama, Kayoko Ni'inuma, Ryuichiro Nishigaki, and Yuichi Sugiyama

Department of Pharmacokinetics & Biopharmaceutics, Toho University School of Pharmaceutical Sciences (M.Y., S.A., R.N.) and Faculty of Pharmaceutical Sciences, University of Tokyo (K.N., Y.S.)

The biliary excretion of pravastatin in normal rats and Eisai hyperbiliruminemic rats (EHBRs) was examined in vivo and in vitro using bile canalicular membrane vesicles (CMVs). In vivo, the total body clearances at steady-state (CLtot) for both rat strains decreased as the infusion rate increased. At the lowest infusion rate, CLtot for normal rats was 1.6 times higher than that for EHBRs. Under this set of conditions, the biliary excretion clearance (CLbile), defined as the biliary excretion rate at steady-state divided by the concentration in the liver (Cliver), for normal rats was 3-fold higher than that for EHBRs. The CLbile fell markedly with increasing Cliver for normal rats and the Michaelis constant (KM) for Cliver was 180 µM; in contrast, the degree of saturation was slight if any in EHBRs. In vitro, the uptake of pravastatin by CMVs prepared from normal rats exhibited clear ATP-dependence, whereas only a minimal effect of ATP was observed on the uptake by CMVs from EHBRs. Transport kinetic studies were performed over a wide range of pravastatin concentration (0.2-10,000 µM) with a tracer tritium-labeled pravastatin. Saturation was observed both in the ATP-dependent (KM: 220 µM) and ATP-independent (KM: 480 µM) uptake by CMVs prepared from normal rats. ATP-dependent uptake of 2,4-dinitrophenyl glutathione, a typical substrate for the canalicular multispecific organic anion transporter (cMOAT), was inhibited by pravastatin in a concentration-dependent manner and the resultant inhibitory constant of pravastatin (170 µM) was comparable with the KM value of ATP-dependent pravastatin uptake itself. In conclusion, biliary excretion of pravastatin is mediated mainly by cMOAT in normal rats. This can explain the decrease in the biliary excretion of pravastatin in EHBRs.

Copyright © 1997 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J Clin PharmacolHome page
T. Ide, T. Sasaki, K. Maeda, S. Higuchi, Y. Sugiyama, and I. Ieiri
Quantitative Population Pharmacokinetic Analysis of Pravastatin Using an Enterohepatic Circulation Model Combined With Pharmacogenomic Information on SLCO1B1 and ABCC2 Polymorphisms
J. Clin. Pharmacol., November 1, 2009; 49(11): 1309 - 1317.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
T. Watanabe, H. Kusuhara, K. Maeda, Y. Shitara, and Y. Sugiyama
Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans
J. Pharmacol. Exp. Ther., February 1, 2009; 328(2): 652 - 662.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
C. Chen, J. L. Stock, X. Liu, J. Shi, J. W. Van Deusen, D. A. DiMattia, R. G. Dullea, and S. M. de Morais
Utility of a Novel Oatp1b2 Knockout Mouse Model for Evaluating the Role of Oatp1b2 in the Hepatic Uptake of Model Compounds
Drug Metab. Dispos., September 1, 2008; 36(9): 1840 - 1845.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. Abe, A. S. Bridges, W. Yue, and K. L. R. Brouwer
In Vitro Biliary Clearance of Angiotensin II Receptor Blockers and 3-Hydroxy-3-methylglutaryl-Coenzyme A Reductase Inhibitors in Sandwich-Cultured Rat Hepatocytes: Comparison with in Vivo Biliary Clearance
J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 983 - 990.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
C. Chen, J. Lin, T. Smolarek, and L. Tremaine
P-glycoprotein Has Differential Effects on the Disposition of Statin Acid and Lactone Forms in mdr1a/b Knockout and Wild-Type Mice
Drug Metab. Dispos., October 1, 2007; 35(10): 1725 - 1729.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
W. Yamashiro, K. Maeda, M. Hirouchi, Y. Adachi, Z. Hu, and Y. Sugiyama
INVOLVEMENT OF TRANSPORTERS IN THE HEPATIC UPTAKE AND BILIARY EXCRETION OF VALSARTAN, A SELECTIVE ANTAGONIST OF THE ANGIOTENSIN II AT1-RECEPTOR, IN HUMANS
Drug Metab. Dispos., July 1, 2006; 34(7): 1247 - 1254.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
L. Huang, Y. Wang, and S. Grimm
ATP-DEPENDENT TRANSPORT OF ROSUVASTATIN IN MEMBRANE VESICLES EXPRESSING BREAST CANCER RESISTANCE PROTEIN
Drug Metab. Dispos., May 1, 2006; 34(5): 738 - 742.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
X.-Y. Chu, J. R. Strauss, M. A. Mariano, J. Li, D. J. Newton, X. Cai, R. W. Wang, J. Yabut, D. P. Hartley, D. C. Evans, et al.
Characterization of Mice Lacking the Multidrug Resistance Protein Mrp2 (Abcc2)
J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 579 - 589.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
K. T. Kivisto, O. Grisk, U. Hofmann, K. Meissner, K.-U. Moritz, C. Ritter, K. A. Arnold, D. Lutjoohann, K. von Bergmann, I. Kloting, et al.
DISPOSITION OF ORAL AND INTRAVENOUS PRAVASTATIN IN MRP2-DEFICIENT TR- RATS
Drug Metab. Dispos., November 1, 2005; 33(11): 1593 - 1596.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. Matsushima, K. Maeda, C. Kondo, M. Hirano, M. Sasaki, H. Suzuki, and Y. Sugiyama
Identification of the Hepatic Efflux Transporters of Organic Anions Using Double-Transfected Madin-Darby Canine Kidney II Cells Expressing Human Organic Anion-Transporting Polypeptide 1B1 (OATP1B1)/Multidrug Resistance-Associated Protein 2, OATP1B1/Multidrug Resistance 1, and OATP1B1/Breast Cancer Resistance Protein
J. Pharmacol. Exp. Ther., September 1, 2005; 314(3): 1059 - 1067.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. Hirano, K. Maeda, S. Matsushima, Y. Nozaki, H. Kusuhara, and Y. Sugiyama
Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin
Mol. Pharmacol., September 1, 2005; 68(3): 800 - 807.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Hirano, K. Maeda, H. Hayashi, H. Kusuhara, and Y. Sugiyama
Bile Salt Export Pump (BSEP/ABCB11) Can Transport a Nonbile Acid Substrate, Pravastatin
J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 876 - 882.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
C. Chen, R. J. Mireles, S. D. Campbell, J. Lin, J. B. Mills, J. J. Xu, and T. A. Smolarek
DIFFERENTIAL INTERACTION OF 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE INHIBITORS WITH ABCB1, ABCC2, AND OATP1B1
Drug Metab. Dispos., April 1, 2005; 33(4): 537 - 546.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
K. A. Hoffmaster, M. J. Zamek-Gliszczynski, G. M. Pollack, and K. L. R. Brouwer
MULTIPLE TRANSPORT SYSTEMS MEDIATE THE HEPATIC UPTAKE AND BILIARY EXCRETION OF THE METABOLICALLY STABLE OPIOID PEPTIDE [D-PENICILLAMINE2,5]ENKEPHALIN
Drug Metab. Dispos., February 1, 2005; 33(2): 287 - 293.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. Sasaki, H. Suzuki, J. Aoki, K. Ito, P. J. Meier, and Y. Sugiyama
Prediction of in Vivo Biliary Clearance from the in Vitro Transcellular Transport of Organic Anions across a Double-Transfected Madin-Darby Canine Kidney II Monolayer Expressing Both Rat Organic Anion Transporting Polypeptide 4 and Multidrug Resistance Associated Protein 2
Mol. Pharmacol., September 1, 2004; 66(3): 450 - 459.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
P. Hansten
Reply
J. Am. Coll. Cardiol., July 16, 2003; 42(2): 397 - 398.
[Full Text] [PDF]

Home page
 JAMAHome page
P. D. Thompson, P. Clarkson, and R. H. Karas
Statin-Associated Myopathy
JAMA, April 2, 2003; 289(13): 1681 - 1690.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Sasaki, H. Suzuki, K. Ito, T. Abe, and Y. Sugiyama
Transcellular Transport of Organic Anions Across a Double-transfected Madin-Darby Canine Kidney II Cell Monolayer Expressing Both Human Organic Anion-transporting Polypeptide (OATP2/SLC21A6) and Multidrug Resistance-associated Protein 2 (MRP2/ABCC2)
J. Biol. Chem., February 15, 2002; 277(8): 6497 - 6503.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
S. V. Vormfelde, M. B. Bottorff, and P. Hansten
Safety of Statins (Hydroxymethyl Glutaryl Coenzyme A Reductase Inhibitors): Different Mechanisms of Metabolism and Drug Transport May Have Clinical Relevance
Arch Intern Med, April 9, 2001; 161(7): 1012 - 1013.
[Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
M. F. Fromm, H.-M. Kauffmann, P. Fritz, O. Burk, H. K. Kroemer, R. W. Warzok, M. Eichelbaum, W. Siegmund, and D. Schrenk
The Effect of Rifampin Treatment on Intestinal Expression of Human MRP Transporters
Am. J. Pathol., November 1, 2000; 157(5): 1575 - 1580.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
R. A. M. H. Van Aubel, R. Masereeuw, and F. G. M. Russel
Molecular pharmacology of renal organic anion transporters
Am J Physiol Renal Physiol, August 1, 2000; 279(2): F216 - F232.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
H. Ishizuka, K. Konno, T. Shiina, H. Naganuma, K. Nishimura, K. Ito, H. Suzuki, and Y. Sugiyama
Species Differences in the Transport Activity for Organic Anions across the Bile Canalicular Membrane
J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1324 - 1330.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
N. Takenaga, M. Ishii, S. Nakajima, T. Hasegawa, R. Iwasa, H. Ishizaki, and T. Kamei
In Vivo Metabolism of a New Anticancer Agent, 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(beta -D-glucopyranosil)5H-indolo [2,3-a]pyrrolo [3,4-c]carbazole-5,7(6H)-dione (NB-506) in Rats and Dogs: Pharmacokinetics, Isolation, Identification, and Quantification of Metabolites
Drug Metab. Dispos., February 1, 1999; 27(2): 205 - 212.
[Abstract] [Full Text]

Home page
 Mol. Pharmacol.Home page
T. Hirohashi, H. Suzuki, K. Ito, K. Ogawa, K. Kume, T. Shimizu, and Y. Sugiyama
Hepatic Expression of Multidrug Resistance-Associated Protein-Like Proteins Maintained in Eisai Hyperbilirubinemic Rats
Mol. Pharmacol., June 1, 1998; 53(6): 1068 - 1075.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.